Subtype
Male Reproductive System Neoplasm
CI-CAN-00001107Explore in graph →
Non-malignant1,533 active trials27 approved drugs58 evidence items
- NCIt
- C3054
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001107Explore in graph →
Clinical trials
6,899 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02366494 | Micro RNAs to Predict Response to Androgen Deprivation Therapy | completed | — | 42 | Medical College of WisconsinOTHER | 1 | Nov 25, 2024 | clinicaltrials |
| NCT03350529 | MRI Guided Transurethral HIFU for Various Prostate Diseases(HIFU-PRO) | completed | N/A | 87 | Turku University HospitalOTHER_GOV | 1 | Nov 25, 2024 | clinicaltrials |
| NCT05438524 | The Performance of MRI Prostate in Men With Different Prostate Health Index (Phi) Values | completed | — | 159 | Chinese University of Hong KongOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT01284920 | A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients | completed | Phase 1 / Phase 2 | 47 | Astellas Pharma IncINDUSTRY | 1 | Nov 21, 2024 | clinicaltrials |
| NCT02124668 | A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy | completed | Phase 2 | 30 | Astellas Pharma Europe B.V.INDUSTRY | 2 | Nov 21, 2024 | clinicaltrials |
| NCT02669771 | Long-Term Specified Drug Use-Results Survey for Xtandi Capsule | completed | — | 1,018 | Astellas Pharma IncINDUSTRY | 1 | Nov 21, 2024 | clinicaltrials |
| NCT02787005 | Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199) | completed | Phase 2 | 388 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 21, 2024 | clinicaltrials |
| NCT03328364 | A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden | completed | — | 211 | Astellas Pharma a/sINDUSTRY | 1 | Nov 21, 2024 | clinicaltrials |
| NCT05381311 | Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study | completed | — | 1,020 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Nov 21, 2024 | clinicaltrials |
| NCT02380274 | Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)(TRUMPET) | completed | — | 1,030 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT03248570 | Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects | completed | Phase 2 | 26 | University of California, San FranciscoOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT04094519 | A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer | completed | Phase 1 | 24 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06362291 | Comparison of MRI AI-cTB Versus Routine cTB in Prostate Cancer Diagnosis: a Prospective Randomized Controlled Trial | completed | N/A | 380 | Peking University First HospitalOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT03535987 | Pilot Cohort Study of Rb-82 Myocardial PET Imaging to Evaluate Coronary Microvascular Dysfunction in Men With Prostate Cancer Receiving Androgen-Deprivation Therapy | completed | — | 18 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT05064670 | Exercise as Medicine for People With Cancer Sweden(EX-MED) | completed | N/A | 200 | Karolinska InstitutetOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT04298112 | PSMA-PET and MRI for Detection of Recurrent Prostate Cancer After Radical Treatment | completed | — | 300 | Norwegian University of Science and TechnologyOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT04790968 | Combined PSMA PET/MRI for Detection of Lymph Node Metastases in High-risk Prostate Cancer Patients | completed | N/A | 90 | Norwegian University of Science and TechnologyOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT02213107 | Enzalutamide & Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer. | completed | Phase 2 | 43 | University of RochesterOTHER | 1 | Nov 13, 2024 | clinicaltrials |
| NCT03414034 | Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 72 | Cardiff OncologyINDUSTRY | 1 | Nov 7, 2024 | clinicaltrials |
| NCT01325506 | Effectiveness of Open and Robotic Prostatectomy(PROSTQA-RP2) | completed | — | 677 | Beth Israel Deaconess Medical CenterOTHER | 1 | Nov 6, 2024 | clinicaltrials |
| NCT03128710 | Prostate Cancer Survey | completed | — | 224 | University of Maryland, BaltimoreOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT05715827 | A Prospective, Single-center, Single-arm, Pivotal Trial of the Medtronic Hugo™ Robotic Assisted Surgery (RAS) System | completed | — | 42 | Medtronic - MITGINDUSTRY | 1 | Nov 5, 2024 | clinicaltrials |
| NCT05895279 | Assessment of Research Digest Impact for Minority with Prostate Cancer, MiCAP Phase III Study(MiCaP) | completed | N/A | 220 | Mayo ClinicOTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT05498623 | MR Fingerprinting for Diagnostic of Prostate Cancer | completed | — | 203 | Norwegian University of Science and TechnologyOTHER | 1 | Nov 1, 2024 | clinicaltrials |
| NCT05759273 | A Study to Observe Demography and the Outcome of Prostate Cancer Patients Treated With 6-month Triptorelin Formulation in Italy(REAL6T) | completed | — | 167 | IpsenINDUSTRY | 1 | Nov 1, 2024 | clinicaltrials |
| NCT01261572 | Study to Find Maintenance Dose for Periodic Administration of ASP3550 | completed | Phase 2 | 155 | Astellas Pharma IncINDUSTRY | 1 | Oct 31, 2024 | clinicaltrials |
| NCT01964170 | A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer | completed | Phase 3 | 234 | Astellas Pharma IncINDUSTRY | 1 | Oct 31, 2024 | clinicaltrials |
| NCT03776968 | A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics | completed | Phase 1 | 47 | Hinova Pharmaceuticals Inc.INDUSTRY | 1 | Oct 23, 2024 | clinicaltrials |
| NCT04978675 | An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate Cancer | completed | Phase 1 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT06566989 | A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008) | completed | Phase 1 | 8 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Oct 23, 2024 | clinicaltrials |
| NCT02495974 | European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)(PREMISE) | completed | — | 1,763 | Astellas Pharma Europe Ltd.INDUSTRY | 16 | Oct 21, 2024 | clinicaltrials |
| NCT04583072 | Stockholm3 Validation Study in a Multi-Ethnic Cohort(SEPTA) | completed | — | 2,152 | Karolinska InstitutetOTHER | 2 | Oct 21, 2024 | clinicaltrials |
| NCT05959564 | A Chatbot Intervention for Reducing HPV Vaccine Hesitancy | completed | N/A | 456 | University of Maryland, College ParkOTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT03507725 | Early Staged Consent Before Prostate Biopsy | completed | N/A | 390 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT05655715 | Checkpoint Inhibitors and SBRT for MCRPC(CheckPRO) | completed | Phase 2 | 90 | Herlev and Gentofte HospitalOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT03204812 | Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT04605276 | Threedimensional Multiparametric Ultrasound for Prostate Cancer Detection(3DmpUS for PCa) | completed | — | 608 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06554639 | A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011) | completed | Phase 1 | 12 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Oct 15, 2024 | clinicaltrials |
| NCT02555397 | Phase 1 Trial of Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer | completed | Phase 1 | 15 | Henry Ford Health SystemOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT04060394 | Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC | completed | Phase 1 / Phase 2 | 49 | Laekna LimitedINDUSTRY | 2 | Oct 10, 2024 | clinicaltrials |
| NCT00207649 | Shared Decision Making: Prostate Cancer Screening | completed | N/A | 641 | Lisa RicharsonFED | 1 | Oct 8, 2024 | clinicaltrials |
| NCT03686683 | Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer(ProVent) | completed | Phase 3 | 532 | DendreonINDUSTRY | 1 | Oct 8, 2024 | clinicaltrials |
| NCT01985828 | CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer | completed | N/A | 83 | Wake Forest University Health SciencesOTHER | 1 | Oct 3, 2024 | clinicaltrials |
| NCT03489057 | Efficacy of a Couple-Focused mHealth Symptom Self-management Program | completed | N/A | 560 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Oct 3, 2024 | clinicaltrials |
| NCT01774071 | Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer | completed | Phase 1 / Phase 2 | 19 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT01794793 | Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies | completed | Phase 4 | 337 | RECORDATI GROUPINDUSTRY | 28 | Oct 1, 2024 | clinicaltrials |
| NCT05181800 | FIRMAGON® Intensive Drug Monitoring | completed | — | 1,454 | Ferring PharmaceuticalsINDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT05520138 | Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) | completed | — | 5,506 | PfizerINDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT02783950 | Genomics in Michigan Impacting Observation or Radiation(G-MINOR) | completed | N/A | 356 | University of Michigan Rogel Cancer CenterOTHER | 1 | Sep 26, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Nov 25, 2024source: clinicaltrials